Goldman Sachs

Kemper Corporation (KMPR) announced a $150 million accelerated share repurchase (ASR) agreement with Goldman Sachs, part of its $550 million authorization. The insurer believes shares are undervalued and the ASR demonstrates confidence in its business. Kemper will pay Goldman Sachs $150 million on August 14, 2025, receiving an initial 2,279,203 shares. The final number depends on the volume-weighted average price of Kemper’s stock. The ASR is expected to conclude within three months. Kemper is a specialized insurer with $13 billion in assets, serving 4.7 million policies.

Bicara Therapeutics (BCAX) will present at the Goldman Sachs 46th Annual Global Healthcare Conference. Management will host a fireside chat on June 10th to discuss the company’s strategy and pipeline. The presentation will focus on their clinical-stage bifunctional therapies, particularly their lead program, ficerafusp alfa, designed to treat solid tumors by overcoming challenges in the tumor microenvironment. A webcast replay will be available.